Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4157.TWO Stock Summary
Top 10 Correlated ETFs
4157.TWO
In the News
4157.TWO Financial details
Company Rating
Buy
Market Cap
10.7B
Income
136.88M
Revenue
123.13M
Book val./share
1.56
Cash/share
1.45
Dividend
-
Dividend %
-
Employees
52
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-80.46
Forward P/E
-
PEG
5.11
P/S
91.18
P/B
14.23
P/C
10.69
P/FCF
-62.66
Quick Ratio
16.76
Current Ratio
17.5
Debt / Equity
0.07
LT Debt / Equity
0.05
-
-
EPS (TTM)
0.19
EPS next Y
-
EPS next Q
-
EPS this Y
-157.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
43.39%
Revenue Q/Q
-7.72%
EPS Q/Q
-2700%
-
-
-
-
SMA20
-0.92%
SMA50
-0.53%
SMA100
3.29%
Inst Own
-
Inst Trans
-
ROA
-16%
ROE
-17%
ROC
-0.15%
Gross Margin
91%
Oper. Margin
-123%
Profit Margin
-135%
Payout
-
Shs Outstand
717.84M
Shs Float
424.56M
-
-
-
-
Target Price
-
52W Range
13.85-18.75
52W High
-13.89%
52W Low
+19.23%
RSI
62.7
Rel Volume
1.51
Avg Volume
1.2M
Volume
1.82M
Perf Week
8.01%
Perf Month
2.65%
Perf Quarter
6.53%
Perf Half Y
7.27%
-
-
-
-
Beta
0.779
-
-
Volatility
0.29%, 0.38%
Prev Close
0.32%
Price
15.5
Change
0%
4157.TWO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.03 | 0.03 | 1.81 | 0.05 | 0.17 | |
Net income per share | -0.41 | -0.56 | 1.08 | -0.33 | 0.19 | |
Operating cash flow per share | -0.48 | -0.34 | 0.88 | -0.03 | 0.03 | |
Free cash flow per share | -0.48 | -0.35 | 0.86 | -0.04 | 0.02 | |
Cash per share | 0.91 | 0.46 | 1.29 | 1.25 | 1.45 | |
Book value per share | 1.14 | 0.62 | 1.75 | 1.35 | 1.56 | |
Tangible book value per share | 1.09 | 0.57 | 1.72 | 1.34 | 1.56 | |
Share holders equity per share | 1.14 | 0.62 | 1.75 | 1.35 | 1.56 | |
Interest debt per share | 0.09 | 0.02 | 0.07 | 0.05 | 0.11 | |
Market cap | 13.19B | 16.38B | 11.04B | 11.51B | 10.79B | |
Enterprise value | 13.12B | 16.34B | 10.73B | 11.3B | 10.49B | |
P/E ratio | -44.61 | -40.46 | 14.23 | -48.51 | 78.91 | |
Price to sales ratio | 649.27 | 699.33 | 8.53 | 317.56 | 87.62 | |
POCF ratio | -38.51 | -67.66 | 17.55 | -540.94 | 520.19 | |
PFCF ratio | -37.95 | -65.39 | 17.89 | -400.42 | 808.37 | |
P/B Ratio | 16.18 | 37.04 | 8.81 | 11.86 | 9.64 | |
PTB ratio | 16.18 | 37.04 | 8.81 | 11.86 | 9.64 | |
EV to sales | 645.82 | 697.47 | 8.29 | 311.92 | 85.19 | |
Enterprise value over EBITDA | -51.91 | -43.87 | 11.85 | -59.92 | -71.31 | |
EV to operating cash flow | -38.3 | -67.48 | 17.05 | -531.32 | 505.73 | |
EV to free cash flow | -37.74 | -65.21 | 17.38 | -393.3 | 785.89 | |
Earnings yield | -0.02 | -0.02 | 0.07 | -0.02 | 0.01 | |
Free cash flow yield | -0.03 | -0.02 | 0.06 | 0 | 0 | |
Debt to equity | 0.08 | 0.04 | 0.04 | 0.04 | 0.07 | |
Debt to assets | 0.07 | 0.03 | 0.04 | 0.04 | 0.06 | |
Net debt to EBITDA | 0.28 | 0.12 | -0.34 | 1.09 | 2.04 | |
Current ratio | 7.88 | 4.13 | 13.71 | 18.5 | 23.19 | |
Interest coverage | -278.67 | -671.85 | 3.59K | -254.27 | -153.65 | |
Income quality | 1.18 | 0.6 | 0.72 | 0.09 | 0.15 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.26 | 3.3 | 0.08 | 2 | 0.8 | |
Research and developement to revenue | 11.01 | 10.65 | 0.22 | 6.56 | 1.52 | |
Intangibles to total assets | 0.04 | 0.05 | 0.01 | 0.01 | 0.01 | |
Capex to operating cash flow | 0.01 | 0.03 | -0.02 | 0.35 | -0.36 | |
Capex to revenue | -0.25 | -0.36 | -0.01 | -0.21 | -0.06 | |
Capex to depreciation | -0.15 | -0.27 | -0.41 | -0.26 | -0.27 | |
Stock based compensation to revenue | 0 | 0.62 | 0.03 | -0.14 | 0.2 | |
Graham number | 3.25 | 2.8 | 6.53 | 3.17 | 2.59 | |
ROIC | -0.32 | -0.84 | 0.57 | -0.21 | -0.13 | |
Return on tangible assets | -0.32 | -0.77 | 0.57 | -0.23 | 0.11 | |
Graham Net | 0.77 | 0.35 | 1.4 | 1.19 | 1.35 | |
Working capital | 614.51M | 296.69M | 1.14B | 897.92M | 1.06B | |
Tangible asset value | 781.25M | 411.82M | 1.23B | 959.02M | 1.11B | |
Net current asset value | 572.9M | 277.33M | 1.09B | 872.26M | 999.44M | |
Invested capital | 0.08 | 0.04 | 0.04 | 0.04 | 0.07 | |
Average receivables | 17.63M | 35.6M | 158.42M | 153.84M | 30.33M | |
Average payables | -88K | -22.29M | -22.29M | -164K | -76K | |
Average inventory | 3.76M | 11.09M | 16.26M | 16.61M | 24.75M | |
Days sales outstanding | 633.51 | 560.25 | 79.2 | 269.93 | 100.39 | |
Days payables outstanding | -8.45 | -4.02K | -5.05 | -14.85 | 0 | |
Days of inventory on hand | 361.16 | 1.33K | 512.95 | 1.5K | 319.2 | |
Receivables turnover | 0.58 | 0.65 | 4.61 | 1.35 | 3.64 | |
Payables turnover | -43.2 | -0.09 | -72.27 | -24.58 | 0 | |
Inventory turnover | 1.01 | 0.28 | 0.71 | 0.24 | 1.14 | |
ROE | -0.36 | -0.92 | 0.62 | -0.24 | 0.12 | |
Capex per share | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.01 | 0.14 | 0.01 | 0.01 | |
Net income per share | -0.16 | -0.07 | 0.01 | -0.01 | 0.26 | |
Operating cash flow per share | -0.12 | -0.04 | 0.02 | -0.07 | 0.12 | |
Free cash flow per share | -0.13 | -0.04 | 0.01 | -0.07 | 0.12 | |
Cash per share | 1.25 | 1.2 | 1.21 | 0.96 | 1.45 | |
Book value per share | 1.35 | 1.28 | 1.33 | 1.06 | 1.56 | |
Tangible book value per share | 1.34 | 1.26 | 1.31 | 1.06 | 1.56 | |
Share holders equity per share | 1.35 | 1.28 | 1.33 | 1.06 | 1.56 | |
Interest debt per share | 0.05 | 0.04 | 0.12 | 0.09 | 0.1 | |
Market cap | 11.51B | 10.75B | 12.8B | 12.45B | 10.8B | |
Enterprise value | 11.3B | 10.54B | 12.74B | 12.44B | 10.5B | |
P/E ratio | -25.62 | -53.51 | 319.83 | -363.75 | 14.55 | |
Price to sales ratio | 2.43K | 1.87K | 128.64 | 1.34K | 1.26K | |
POCF ratio | -129 | -390.61 | 1.15K | -206.05 | 125.75 | |
PFCF ratio | -126.88 | -367.49 | 1.42K | -198.8 | 127.73 | |
P/B Ratio | 11.86 | 11.73 | 13.44 | 13.67 | 9.66 | |
PTB ratio | 11.86 | 11.73 | 13.44 | 13.67 | 9.66 | |
EV to sales | 2.39K | 1.83K | 128.12 | 1.34K | 1.22K | |
Enterprise value over EBITDA | -113.67 | -243.39 | 496.18 | -7.27K | -133.24 | |
EV to operating cash flow | -126.7 | -382.71 | 1.15K | -205.87 | 122.26 | |
EV to free cash flow | -124.62 | -360.06 | 1.42K | -198.63 | 124.18 | |
Earnings yield | -0.01 | 0 | 0 | 0 | 0.02 | |
Free cash flow yield | -0.01 | 0 | 0 | -0.01 | 0.01 | |
Debt to equity | 0.04 | 0.03 | 0.09 | 0.09 | 0.07 | |
Debt to assets | 0.04 | 0.03 | 0.08 | 0.08 | 0.06 | |
Net debt to EBITDA | 2.06 | 5.02 | -2.02 | 6.3 | 3.81 | |
Current ratio | 18.5 | 13.63 | 19.23 | 17.5 | 23.19 | |
Interest coverage | -591.76 | -316.84 | 132.04 | -19.37 | -207.97 | |
Income quality | 0.79 | 0.55 | 0.61 | 7.06 | 0.46 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.44 | 4.08 | 0.22 | 2.32 | 3.77 | |
Research and developement to revenue | 15.47 | 5.81 | 0.46 | 5.22 | 6.92 | |
Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Capex to operating cash flow | 0.02 | 0.06 | -0.19 | 0.04 | -0.02 | |
Capex to revenue | -0.31 | -0.3 | -0.02 | -0.24 | -0.15 | |
Capex to depreciation | -0.21 | -0.24 | -0.29 | -0.33 | -0.21 | |
Stock based compensation to revenue | 0.13 | 0.37 | 0.05 | 0.81 | 1.15 | |
Graham number | 2.18 | 1.42 | 0.65 | 0.49 | 3.01 | |
ROIC | -0.1 | -0.05 | 0.01 | -0.01 | -0.07 | |
Return on tangible assets | -0.11 | -0.05 | 0.01 | -0.01 | 0.15 | |
Graham Net | 1.19 | 1.13 | 1.1 | 0.88 | 1.35 | |
Working capital | 897.92M | 845.37M | 880.7M | 850.58M | 1.06B | |
Tangible asset value | 959.02M | 905.23M | 941.13M | 897.82M | 1.11B | |
Net current asset value | 872.26M | 828.33M | 809.5M | 783.49M | 999.44M | |
Invested capital | 0.04 | 0.03 | 0.09 | 0.09 | 0.07 | |
Average receivables | 25.16M | 28.62M | 36.97M | 43.53M | 38.71M | |
Average payables | -152K | -11.23M | -11.23M | -152K | -76K | |
Average inventory | 16.17M | 15.56M | 15.84M | 24.13M | 33.25M | |
Days sales outstanding | 510.34 | 475.52 | 39.36 | 421.07 | 354.74 | |
Days payables outstanding | -8.38 | -778.19 | -4.17 | -3.85 | 0 | |
Days of inventory on hand | 846.56 | 550.15 | 436.74 | 819.81 | 362.91 | |
Receivables turnover | 0.18 | 0.19 | 2.29 | 0.21 | 0.25 | |
Payables turnover | -10.74 | -0.12 | -21.57 | -23.37 | 0 | |
Inventory turnover | 0.11 | 0.16 | 0.21 | 0.11 | 0.25 | |
ROE | -0.12 | -0.05 | 0.01 | -0.01 | 0.17 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
4157.TWO Frequently Asked Questions
What is TaiGen Biopharmaceuticals Holdings Limited stock symbol ?
TaiGen Biopharmaceuticals Holdings Limited is a TW stock and trading under the symbol 4157.TWO
What is TaiGen Biopharmaceuticals Holdings Limited stock quote today ?
TaiGen Biopharmaceuticals Holdings Limited stock price is $15.5 today.
Is TaiGen Biopharmaceuticals Holdings Limited stock public?
Yes, TaiGen Biopharmaceuticals Holdings Limited is a publicly traded company.